Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 448,000 shares, a drop of 52.7% from the June 30th total of 947,400 shares. Based on an average daily volume of 4,950,000 shares, the days-to-cover ratio is currently 0.1 days.
Sonoma Pharmaceuticals Stock Down 7.3 %
NASDAQ SNOA traded down $0.03 during trading on Friday, hitting $0.35. The stock had a trading volume of 719,831 shares, compared to its average volume of 4,188,936. The company has a market capitalization of $6.67 million, a PE ratio of -0.48 and a beta of 1.38. The firm has a 50 day moving average price of $0.25 and a 200 day moving average price of $0.19. Sonoma Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $1.15.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last announced its quarterly earnings data on Monday, June 17th. The company reported ($0.07) EPS for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 64.15% and a negative net margin of 37.97%. The company had revenue of $3.44 million for the quarter. On average, sell-side analysts anticipate that Sonoma Pharmaceuticals will post -0.2 earnings per share for the current year.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
Read More
- Five stocks we like better than Sonoma Pharmaceuticals
- How to Effectively Use the MarketBeat Ratings Screener
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Want to Profit on the Downtrend? Downtrends, Explained.
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.